Generic Medicine Info
Indications and Dosage
Production of cycloplegia
Adult: For refraction: As 1% solution: Instil 1 or 2 drops into the eye(s); repeat after 5 minutes. An additional drop may be administered if the patient is not examined within 20-30 minutes. Additional doses may be required in patients with heavily pigmented eyes.

Production of mydriasis
Adult: For funduscopic examination: As 0.5% solution: Instil 1 or 2 drops into the eye(s) 15-20 minutes before examination. Higher strength or additional doses may be required in patients with heavily pigmented eyes.
Known or suspected angle-closure glaucoma, narrow anterior chamber angle.
Special Precautions
Patient with inflamed eye(s), increased intraocular pressure; hypersensitivity to belladonna alkaloids or other anticholinergic drugs. Pregnancy and lactation.
Adverse Reactions
Significant: Transient increase in intraocular pressure, CNS disturbances.
Cardiac disorders: Tachycardia, bradycardia, palpitations, arrhythmia.
Eye disorders: Blurred vision, photophobia, eye pain or irritation, superficial punctate keratitis, transient stinging, ocular hyperaemia.
Gastrointestinal disorders: Dry mouth, nausea, vomiting, reduced gastrointestinal motility, constipation.
General disorders and administration site conditions: Prolonged mydriatic effect.
Immune system disorders: Allergic reactions.
Musculoskeletal and connective tissue disorders: Muscle rigidity.
Nervous system disorders: Dizziness, headache.
Renal and urinary disorders: Urinary urgency, difficulty, and retention.
Skin and subcutaneous tissue disorders: Rash, dry skin.
Vascular disorders: Hypotension, syncope, flushing, pallor.
Patient Counseling Information
Remove contact lenses before application and wait for at least 15 minutes before reinsertion. This drug may cause drowsiness, blurred vision and sensitivity to light, if affected, do not drive or operate machinery.
Monitoring Parameters
Determine intraocular pressure and estimate the depth of the angle of the anterior chamber before initiation of therapy.
Drug Interactions
May interfere with the ocular antihypertensive effects of pilocarpine, carbachol or ophthalmic cholinesterase inhibitors. Effects may be enhanced when used concomitantly with other drugs having antimuscarinic properties (e.g. amantadine, certain antihistamines, antipsychotics, TCAs).
Description: Tropicamide is a synthetic tertiary amine antimuscarinic which blocks the responses of the sphincter muscle of the iris and ciliary muscle to cholinergic stimulation resulting in pupillary dilation. It also causes paralysis of accommodation at higher concentrations.
Onset: Mydriasis: Approx 20-40 minutes. Cycloplegia: 20-35 minutes (peak).
Duration: Mydriasis: Approx 6-7 hours. Cycloplegia: 50 minutes to 6 hours.
Chemical Structure

Chemical Structure Image

Source: National Center for Biotechnology Information. PubChem Compound Summary for CID 5593, Tropicamide. Accessed Jan. 25, 2021.

Store between 8-27°C. Do not refrigerate or freeze. Protect from light. Storage recommendations may vary among countries or individual products. Refer to specific product guidelines.
MIMS Class
Mydriatic Drugs
ATC Classification
S01FA06 - tropicamide ; Belongs to the class of anticholinergics used as mydriatics and cycloplegics.
Alcon Laboratories New Zealand Limited. Mydriacyl 0.5% and 1% Eye Drops data sheet 17 August 2020. Medsafe. Accessed 05/01/2021.

Anon. Tropicamide (EENT). AHFS Clinical Drug Information [online]. Bethesda, MD. American Society of Health-System Pharmacists, Inc. Accessed 05/01/2021.

Anon. Tropicamide. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. Accessed 05/01/2021.

Bausch & Lomb NZ Ltd. Minims Tropicamide Eye Drops Solution 0.5% and 1% data sheet 30 November 2018. Medsafe. Accessed 05/01/2021.

Buckingham R (ed). Tropicamide. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. Accessed 05/01/2021.

Minims Tropicamide 0.5% (Bausch & Lomb UK Limited). MHRA. Accessed 05/01/2021.

Mydriacyl 0.5% Eye Drops Solution (Alcon Eye Care UK Limited). MHRA. Accessed 05/01/2021.

Mydriacyl 1% Sterile Ophthalmic Solution (Alcon Laboratories [Malaysia] Sdn. Bhd.). National Pharmaceutical Regulatory Agency - Ministry of Health Malaysia. Accessed 19/01/2021.

Tropicamide Solution/Drops (Sandoz Inc.). DailyMed. Source: U.S. National Library of Medicine. Accessed 05/01/2021.

Disclaimer: This information is independently developed by MIMS based on Tropicamide from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2022 MIMS. All rights reserved. Powered by
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in